期刊文献+

QRDR点突变致解脲脲原体耐巴洛沙星的探讨

The Approach on the Resistance of Ureaplasma Urealyticum to Balofloxacin Incurred by the Spot Mutation of QRDRs
下载PDF
导出
摘要 目的研究解脲脲原体(Uu)编码II型拓扑异构酶的基因喹诺酮耐药决定区(QRDR)突变与巴洛沙星耐药的关系。方法对喹诺酮类药物敏感的Uu临床分离株用巴洛沙星进行耐药诱导培养,使之产生第一代和第二代耐药突变株。检测巴洛沙星对Uu标准株、临床分离株、第一代和第二代耐药突变株的最低抑菌浓度(MIC),并对这些菌株的QRDR进行PCR扩增后测序。结果第一代耐药突变株均在编码拓扑异构酶IV基因的QRDR上发生了点突变;第二代耐药突变株则在继承了前代的点突变之后,均在编码DNA促旋酶基因的QRDR上发生了不同的点突变。结论QRDR的点突变可导致Uu对巴洛沙星产生耐药;巴洛沙星对Uu的首要靶酶是拓扑异构酶IV。 Objective To study the correlations between mutations of the quinolone resistance - determining region(QRDR) gene that encodes type Ⅱ topoisomerase of Ureaplasma urealyticum and resistance to Balofloxacin. Methods Clinical isolated strain of Ureaplasma urealyticmn which was sensitive to quinolones was induced by Balofloxacin, then the first and the second generations of resistant mutants were gotten. The MICs of Balofloxacin against Ureaplasma urealyticum reference strain, the clinical isolate as well as the resistant mutants were determined. And QRDRs gene of these Ureaplasma urealyticmn were gotten by PCR, then their sequences were analyzed. Results Each of the first generation of resistant mutants had a spot mutation in the QRDR gene that encodes topoisomerase IV; And the second generation of resistant mutants not only inherited the mutations of their previous gener- ation, but also had an additional mutation in the QRDR gene that encodes DNA gyrase. Conclusion The mutations of QRDRs can resuh in the resistance to Balofloxacin in Ureaplasma urealyticum; The primary target of Balofloxacin in Urcaplasma urealyticmn is topoisomemse Ⅳ.
作者 王堃 罗祎敏
出处 《南华大学学报(医学版)》 2008年第1期15-18,共4页 Journal of Nanhua University(Medical Edition)
关键词 解脲脲原体 巴洛沙星 喹诺酮耐药决定区 突变 耐药 Ureaplasma urcalyticum Balofloxacin QRDR mutation drug resistance
  • 相关文献

参考文献9

  • 1Biswas S, Raoult D, Rolain JM. Molecular mechanisms of resistance to antibiotics in Bartonella bacilliformis [ J ]. J Antimicrob Chemother, 2007,59(6) : 1065 - 1070.
  • 2Hawkey PM. Mechanisms of quinolone action and microbial response[ J]. J Antimicrob Chcnlother, 2003,51 ( S1) : 29 - 35.
  • 3Drlica K, Malik M. Fluoroquinolones: action and resistance[J]. Curr Top Med Chem, 2003,3(3):249 - 282.
  • 4Bebear CM, Renaudin H, Charron A, et al. DNA gyrase and topoisomerase Ⅳ mutations in clinical isolates of ureaplasma spp and mycoplasma hominis resistant to fiuoroquinolones[J ]. Anfimicrobial Agents and Chemotherapy, 2003,47(10) :3323 - 3325.
  • 5Hsu YH, Chung MW, Li TK. Distribution of gyrase and topoisomerase Ⅳ on bacterial nucleoid: imphcations for nncleoid organization[ J ]. Nucleic Acids Res, 2006 6 ; 34 (10) :3128 - 3138.
  • 6Hu LF, Li JB, Ye Y, et al. Mutations in the GyrA subunit of DNA gyrase and the ParC subunlt of topoisomerase Ⅳ in clinical strains of fluoroquinolone - resistant Shigella in Anhui[J]. J Microbiol, 2007,45(2):168- 170.
  • 7Kim KS, Kim 314, Kiln DY, et al. Moleular cloning of the DNA gyrase genes from Methylovorus sp. strain SS1 and tile nleehanism of intrinsic quinolone resistance in nlethylotrophic bacteria[J].Mol Cells, 2005,20 ( 3 ) : 392 -400.
  • 8Gruson D, Pereyre S, Renaudin H, et al. In vitro development of resistance to six and four fluoroquinolones in mycoplasma pneumoniac and mycoplasma hominis, respectively[J]. Antimicrobial Agents and Chemotherapy, 2005,49(3): 1190- 1193.
  • 9Laponogov I,Veselkov DA,Sohi MK,et al.Breakage-reunion domain of Streptococcus pneumoniac topoisomerase Ⅳ:crystal structure of a gram-positive quinolone target [J]. PLoS ONE, 2007, 2(3):e301.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部